ライフサイエンスコーパス: liver toxicity

1 ide effects like bone marrow suppression and liver toxicity.

2 be withdrawn within weeks on the grounds of liver toxicity.

3 a and IL-18 fully protected the mice against liver toxicity.

4 ect that needs to be overcome is nonspecific liver toxicity.

5 (p for trend < 0.0001), indicating possible liver toxicity.

6 to liver cells and results in dose-limiting liver toxicity.

7 Dose escalation was limited by liver toxicity.

8 rstanding how covalent binding could lead to liver toxicity.

9 tifying patients most susceptible to tacrine liver toxicity.

10 lpha-amanitin have been limited owing to its liver toxicity.

11 dard of care (sorafenib), without increasing liver toxicity.

12 ATRA and idarubicin, with a low incidence of liver toxicity.

13 onistic antibodies resulted in dose-limiting liver toxicity.

14 cing secondary disease such as steatosis and liver toxicity.

15 There have also been suspicions about liver toxicity.

16 ed CYP2E1 plays an important role in alcohol liver toxicity.

17 veral diseases, including cancer and alcohol liver toxicity.

18 pl2 in sterile inflammation and drug-induced liver toxicity.

19 L12-, IFN-gamma-, and concanavalin A-induced liver toxicity.

20 ppresses proinflammatory cytokine-associated liver toxicity.

21 served antitumor efficacy from the on-target liver toxicity.

22 e (C-C motif) ligand 5 (CCL5) and subsequent liver toxicity.

23 persistence of activated T cells may lead to liver toxicity.

24 mmadeltaT cells during AdLacZ-mediated acute liver toxicity.

25 ion-defective adenovirus (Ad)-mediated acute liver toxicity.

26 ated in the development of Ad-mediated acute liver toxicity.

27 t-market attrition of pharmaceuticals due to liver toxicity.

28 trains in the study of acetaminophen-induced liver toxicity.

29 emplified using a study on hydrazine-induced liver toxicity.

30 and Drug Administration (FDA) for reasons of liver toxicity.

31 d memory T-cell responses with no measurable liver toxicity.

32 rved for tolerability, glycemic control, and liver toxicity.

33 th ipilimumab (anti-CTLA4), with significant liver toxicities.

34 peripheral neuropathy (2 patients, 5%), and liver toxicity (2 patients, 5%).

35 outcomes (hyponatremia 44% vs 67% (p=0.29); liver toxicity 6% vs 0% (p=1.0)).

36 n unraveling the mechanisms underlying early liver toxicity after adenovirus infusion, particularly t

37 le for gammadeltaT cells in initiating acute liver toxicity after AdLacZ administration, driven in pa

38 We examined the hypothesis that liver toxicity after cyclophosphamide and total body irr

39 Management and prevention of liver toxicity among HIV-infected patients treated with

40 discovered common biomarkers of drug-induced liver toxicity among six heterogeneous compounds.

41 kylating agent azoxymethane resulted in both liver toxicity and an increased incidence of precancerou

42 hich stem from diverse etiologies, result in liver toxicity and fibrosis and may progress to cirrhosi

43 s exposure is one of the primary factors for liver toxicity and hepatocarcinoma.

44 pplications is restricted due to significant liver toxicity and immunogenicity.

45 cumulation resulted in significantly reduced liver toxicity and increased transduction efficiency of

46 tion, using a murine model of CCl(4)-induced liver toxicity and mice genetically deficient in C5.

47 d of follow-up (18-53 weeks), only transient liver toxicity and no renal toxicity had been observed.

48 lites of cyclophosphamide leads to increased liver toxicity and nonrelapse mortality and lower overal

49 amide synthases (CerS) and causes kidney and liver toxicity and other disease.

50 umulate these chemical pollutants and suffer liver toxicity and pathology.

51 5 x 10(5)CFU of Brucella, (ii) the extent of liver toxicity, and (iii) the minimum immunizing dose of

52 luding adverse events with serious outcomes, liver toxicity, and muscle toxicity without rhabdomyolys

53 tritional abnormalities, including alopecia, liver toxicity, and runting.

54 he MONO study were fever, hypotension, acute liver toxicity, and vascular leak syndrome.

55 Early liver toxicity as determined by serum glutamic-pyruvic t

56 Acute liver toxicity (as measured with liver enzyme elevation)

57 f urelumab has been hampered by inflammatory liver toxicity at doses >1 mg/kg.

58 n dosing algorithms were not associated with liver toxicity at EOT.

59 No clinical symptoms or signs of liver toxicity attributable to vitamin A excess were det

60 Obesity increases risk for liver toxicity by the anti-leukemic agent asparaginase,

61 f HIV infection, increasing the incidence of liver toxicity caused by antiretroviral medications.

62 at such a discrepancy could be due to severe liver toxicity caused by bortezomib and LPS co-treatment

63 Liver toxicity caused by high-dose myeloablative therapy

64 IH greatly exacerbated acetaminophen-induced liver toxicity, causing fulminant hepatocellular injury.

65 Iron overload is associated with liver toxicity, cirrhosis, and hepatocellular carcinoma

66 The observed liver toxicity confirms the results of gamma camera and

67 refore, we investigated whether FIAU-induced liver toxicity could be detected in chimeric TK-NOG mice

68 FIAU-induced liver toxicity could be readily detected using chimeric

69 ate-phase drug developmental failures due to liver toxicity could potentially be reduced through the

70 The lack of relevant liver toxicity despite high applied (90)Y activities and

71 Liver toxicity did not develop in control mice that were

72 es some protection against cardiotoxicity or liver toxicity during cancer treatment.

73 eated with azoxymethane (AOM) and markers of liver toxicity examined.

74 Liver toxicity following an overdose of acetaminophen is

75 The experimental liver toxicity from the different treatments was confirm

76 Liver toxicity (hepatotoxicity) is a critical issue in d

77 ical consequences derived from HAART-related liver toxicity, hypersensitivity reactions and lactic ac

78 pt that it resulted in serologic evidence of liver toxicity in 6 percent of the women.

79 V) serotype 2 vectors has been implicated in liver toxicity in a recent human gene therapy trial of h

80 The results of antidepressant liver toxicity in all phases of clinical trials should b

81 ubsequent autologous recovery, and transient liver toxicity in dogs treated with (211)At doses less t

82 44 mg/kg/d po) for 14 d, which did not cause liver toxicity in human trial participants, did not caus

83 In addition, we observed less liver toxicity in mice injected with the Av4orf3nBg vect

84 y in human trial participants, did not cause liver toxicity in mice with humanized livers.

85 cted susceptibility to acetaminophen-induced liver toxicity in mice.

86 The approach is illustrated with a study of liver toxicity in rats using NMR spectra of urine follow

87 to one of 13 endpoints indicative of lung or liver toxicity in rodents, or of breast cancer, multiple

88 icantly reduced infection of liver cells and liver toxicity in vivo.

89 We previously observed liver toxicity-including hepatocyte turnover, loss of ge

90 ow that PPARbeta/delta is protective against liver toxicity induced by AOM and CCl(4), suggesting tha

91 In contrast to evidence of liver toxicity, inflammation, and cellular infiltration

92 ose, its importance in acetaminophen-induced liver toxicity is not well understood, primarily due to

93 Liver toxicity is the major concern for use of recombina

94 Acetaminophen-induced liver toxicity is the most frequent precipitating cause

95 The FDA's Liver Toxicity Knowledge Base (LTKB) evaluated >1000 dru

96 s National Center for Toxicological Research Liver Toxicity Knowledge Base (NCTR-LTKB), the inhibitor

97 n sensitivity to TRAIL, and that substantial liver toxicity might result if TRAIL were used in human

98 Only transient, mostly minor liver toxicity (no grade 4) was recorded.

99 The hazards of liver toxicity, nonrelapse mortality, tumor relapse, and

100 Also, no signs of liver toxicity occurred after the rAAV-AGA administratio

101 OLG was strongly associated with VPA-induced liver toxicity (odds ratio = 23.6, 95% confidence interv

102 Updated information on liver toxicity of current antiretroviral drugs, includin

103 a high response rate (85%) without increased liver toxicity of grade 3 or higher (6% vs. 12% in the p

104 an important causal role in the nonspecific liver toxicity of LMB-2.

105 kDa gene had no significant influence on the liver toxicity of the vectors in this system.

106 GI, and liver (18%; 12 patients) and grade 4 liver toxicities (one patient) were also observed.

107 After liver toxicity (one death from venoocclusive disease [VO

108 No significant liver toxicity or cFIX-specific antibodies have been det

109 the XRCC3 241Met variant had reduced risk of liver toxicity (OR = 0.32; 95%CI, 0.11-0.95).

110 The overall gastrointestinal and liver toxicity profile was consistent with the profile i

111 ence of hyponatraemia (sNa</=132 mmol/L) and liver toxicity (proportion of patients alanine transamin

112 All evidence of liver toxicity resolved except for persistent hypofibrin

113 imary hepatocytes for use in high-throughput liver toxicity studies.

114 NMR spectroscopic study of hydrazine-induced liver toxicity study in rats.

115 the IL-2 mutant also exhibits lower lung and liver toxicity than does wtIL-2 when used at high doses

116 s substantial, dose-dependent, dose-limiting liver toxicity that was manifest as elevated serum trans

117 and tumorigenesis, and the relevance of TCS liver toxicity to humans should be evaluated.

118 ration of HAdV-5 vectors can result in acute liver toxicity, transaminitis, thrombocytopenia, and inj

119 ed stop criteria: one IV-D patient developed liver toxicity; two patients in each group developed bra

120 Liver toxicity was also blocked by indomethacin, which a

121 Liver toxicity was assessed through physical examination

122 In addition, the LMB-2-induced liver toxicity was blocked by a specific TNF binding pro

123 Dose-dependent liver toxicity was detected in chimeric mice treated wit

124 APAP-induced liver toxicity was mirrored by significantly increased p

125 ur polyamides after injection, dose-limiting liver toxicity was only observed for three polyamides.

126 Liver toxicity was scored by the development of sinusoid

127 grade 3 or 4 thrombocytopenia, asthenia, and liver toxicity was significantly higher in the experimen

128 Grade 3 to 4 hematologic and liver toxicities were greater in the GO arm.

129 Severe TRAEs associated with renal and liver toxicities were uncommon.

130 doses of 3.6 to 8.8 mCi/kg Bi, but signs of liver toxicity were noted in all dogs.

131 erase (GGT) and direct bilirubin, markers of liver toxicity, were obtained from blood samples collect

132 Importantly, AdMKTK + GCV did not induce liver toxicity, whereas substantial toxicity was seen wi

133 receptor agonist (GW3965) and abolished its liver toxicity while still preserving its therapeutic fu

134 role of PPARbeta/delta in chemically induced liver toxicity, wild-type and PPARbeta/delta-null mice w

135 However, concern regarding liver toxicity with systemic therapy makes local deliver

136 ; and 5) safety concerns regarding increased liver toxicity with ximelagatran without a significant o

137 of the mechanisms that lead to idiosyncratic liver toxicity would be extremely beneficial for the dev